Skip to content
1st Counsel – Lifestyle
Author:
Celcuity Inc.
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
March 9, 2026
←
Previous Page
1
2